Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Eton Pharmaceuticals, Inc. (ETON) had Revenue of $39.01M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$39.01M
Net Income	$-3.82M
Cost of Goods Sold	$15.60M
Gross Profit	$23.41M
Operating Expenses	$41.61M
Operating Income	$-2.60M
Non-Operating Income/Expense	$-1.21M
Pre-Tax Income	$-3.81M
Normalized Pre-Tax Income	$-3.81M
Income after Taxes	$-3.82M
Income from Continuous Operations	$-3.82M
Consolidated Net Income/Loss	$-3.82M
Normalized Income after Taxes	$-3.82M
EBIT	$-2.60M
EBITDA	$-0.34M
Weighted-Average Shares Outstanding (Basic)	25.89M
Weighted-Average Shares Outstanding (Diluted)	25.89M
Earnings per Share (EPS) (Basic)	$-0.15
Earnings per Share (EPS) (Diluted)	$-0.15
Balance Sheet Financials
Current Assets	$41.02M
Property, Plant, and Equipment	$0.03M
Long-Term Assets	$35.10M
Total Assets	$76.12M
Current Liabilities	$19.95M
Long-Term Debt	$29.81M
Long-Term Liabilities	$31.75M
Total Liabilities	$51.70M
Common Equity	$24.43M
Tangible Shareholders Equity	$-10.45M
Shareholders Equity	$24.43M
Common Shares Outstanding	26.71M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$0.97M
Cash Flow from Investing Activities	$-40.01M
Cash Flow from Financial Activities	$32.59M
Beginning Cash	$21.39M
End Cash	$14.94M
Increase/Decrease in Cash	$-6.45M
Stock-Based Compensation	$3.17M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.06
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.55
Debt to Equity Ratio	1.22
Gross Margin	60.01%
Operating Margin	-6.66%
EBIT Margin	-6.66%
EBITDA Margin	-0.88%
Pre-Tax Profit Margin	-9.76%
Profit Margin	-9.80%
Free Cash Flow	$0.94M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.51
Inventory Turnover	1.02
Receiveable Turnover	7.28
Days Sales in Receivables	50.16
Return on Equity	-15.65%
Return on Tangible Equity	36.57%
Return on Assets	-5.02%
Return on Investments	-7.05%
Book Value Per Share	$0.91
Free Cash Flow per Share	$0.04
Operating Cash Flow per Share	$0.04

Data from Zacks Investment Research, Inc.